Endothall

Endothall

SCHEMBL3494764

O=C(O)[C@@H]1[C@H](C(=O)O)[C@H]2CC[C@@H]1O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TFPI2 P48307 7/20 1.00
LMNA P02545 2/20 1.00
KDM4E B2RXH2 1/20 1.00
GMNN O75496 1/20 1.00
PMP22 Q01453 1/20 1.00
TP53 P04637 1/20 1.00
TSHR P16473 1/20 1.00
NFKB1 P19838 1/20 1.00
THPO P40225 1/20 1.00
PPM1B O75688 3/20 0.68
PTPN1 P18031 3/20 0.68
PPP1CC P36873 3/20 0.68
PPP1CA P62136 1/20 0.59
PPP5C P53041 2/20 0.57
PPP2CA P67775 1/20 0.57
NPY4R P50391 1/20 0.57
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
BLM P54132 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Endothall SCHEMBL9464699 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL3495744 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL11394413 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL55158 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL8536404 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL9464559 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL13480837 1.00 TFPI2 (1.00) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL11143562 0.97 TFPI2 (0.94) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL29512510 0.97 TFPI2 (0.94) TFPI2LMNAKDM4EGMNNPMP22
Endothall SCHEMBL14861262 0.97 TFPI2 (0.94) TFPI2LMNAKDM4EGMNNPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
CN-114845553-A Method for weed growth control 马斯特格罗生物制品公司 2022-08-02 CN disclosed
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2019-09-03 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 EP disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 US disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 US disclosed
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. 2015-02-12 US disclosed
US-5241104-A Reacting acid anhydride with arylacetic acid derivatives; for preparing optically active prostaglandins SHIONOGI & CO., LTD. (JP) 1993-08-31 US disclosed
EP-0373949-B1 MONO ESTERS OF DICARBOXYLIC ACIDS, THEIR PREPARATION AND USE SHIONOGI & CO (JP) 1993-08-25 EP disclosed
EP-0373931-B1 MONOESTERS OF ARYLACETIC ACID, THEIR PRODUCTION AND USE SHIONOGI & CO (JP) 1993-07-28 EP disclosed
US-5183909-A Useful as intermediate for production of prostaglandins, terpenes, aminosugars, nucleotides and alkaloids SHIONOGI & COMPANY, LTD. (JP) 1993-02-02 US disclosed
US-5175341-A Bicyclo 2.2.2!heptanedicarboxylic acid derivatives SHIONOGI & CO., LTD. (JP) 1992-12-29 US disclosed
US-5117039-A Intermediates for Prostaglandin Preparation SHIONOGI & CO., LTD. (JP) 1992-05-26 US disclosed
US-5047574-A CHEMICAL INTERMEDIATES FOR OPTICALLY ACTIVE PRODUCTS, MEDICINES SHIONOGI & CO., LTD. (JP) 1991-09-10 US disclosed
EP-0373931-A2 Monoesters of arylacetic acid, their production and use SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1990-06-20 EP disclosed
EP-0373949-A1 Mono esters of dicarboxylic acids, their preparation and use SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1990-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885LMNA 2628/4885KDM4E 1204/4885
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885LMNA 2628/4885KDM4E 1204/4885
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885LMNA 2628/4885KDM4E 1204/4885
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885LMNA 2628/4885KDM4E 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.